Medicus Pharma Ltd. Common Stock Cash Flow Conversion Efficiency
Medicus Pharma Ltd. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Medicus Pharma Ltd. Common Stock (MDCX) has a cash flow conversion efficiency ratio of 4.078x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.96 Million) by net assets ($-1.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Medicus Pharma Ltd. Common Stock (2010–2025)
Cash flow conversion efficiency of Medicus Pharma Ltd. Common Stock from 2010 to 2025. This chart illustrates how Medicus Pharma Ltd. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Medicus Pharma Ltd. Common Stock for real-time trading data and today's change.
Medicus Pharma Ltd. Common Stock Cash Flow Conversion Ratio Explained
Medicus Pharma Ltd. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Medicus Pharma Ltd. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medicus Pharma Ltd. Common Stock ranked by their cash flow conversion efficiency. Also see MDCX market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ECOUP OYJ EO 1
F:62H
|
N/A |
|
Pivotal Metals Ltd
AU:PVT
|
-0.038x |
|
CLASS 1 NICKEL+TECH.LTD
F:77C
|
0.123x |
|
Renew Holdings plc
LSE:RNWH
|
0.122x |
|
The House of Agriculture Spiroy S.A.
AT:SPIR
|
0.757x |
|
Aspire BioPharma, Inc.
NASDAQ:ASBP
|
-0.180x |
|
Boa Concept SA
PA:ALBOA
|
0.010x |
|
REC Silicon ASA
OL:RECSI
|
0.174x |
Annual Cash Flow Conversion Efficiency for Medicus Pharma Ltd. Common Stock (2010–2025)
The table below shows the annual cash flow conversion efficiency of Medicus Pharma Ltd. Common Stock from 2010 to 2025. Review Medicus Pharma Ltd. Common Stock (MDCX) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $37.31K | $-22.78 Million | -610.457x | -18574.34% |
| 2024-12-31 | $3.13 Million | $-10.25 Million | -3.269x | +12.63% |
| 2023-12-31 | $1.11 Million | $-4.16 Million | -3.741x | -4417.13% |
| 2022-12-31 | $-12.20 Million | $-1.06 Million | 0.087x | -37.13% |
| 2021-12-31 | $-10.51 Million | $-1.45 Million | 0.138x | -86.91% |
| 2017-12-31 | $-62.65K | $-65.99K | 1.053x | +75.08% |
| 2010-12-31 | $-2.00 Million | $-1.20 Million | 0.602x | -- |
About Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The com… Read more